de
en
de
en
International
About us
BERLIN-CHEMIE
MENARINI Group
Our History
Our Goal
Executive Board
Contact
Responsibility
Code of Conduct
Sustainability & social commitment
Code of practice for business partners
Press
News and Press Releases
Media library
Jobs & Careers
About us
BERLIN-CHEMIE
Manufacturing & Quality assurance
Business Development
MENARINI Group
Our History
Our Goal
Executive Board
Contact
Responsibility
Code of Conduct
Sustainability & social commitment
Code of practice for business partners
Press
News and Press Releases
Media library
Jobs & Careers
Home >>
Contact >>
Purchasing Terms >>
Quality Requirements API / EXC >>
Data Protection Information Notice for Healthcare Professionals >>
Data Protection Information Notice for Patients >>
Privacy >>
Disclaimer >>
Imprint >>
Sitemap >>
Change cookie settings »
Press
|
News and Press Releases
|
News Detail
News and Press Releases
Media library
CHMP Adopted Positive Opinion for ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
11/13/2020
Read more
Menarini Group: committed to fighting today's COVID-19 pandemic with an eye to averting similar health crises in the future
10/27/2020
Read more
Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant
7/23/2020
Read more
Menarini Group Completes Acquisition of Stemline Therapeutics
6/10/2020
Read more
Menarini invests 150 million euros in a new pharmaceutical plant in Italy
6/6/2020
Read more
Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million
5/4/2020
Read more
Helsinn Group Grants Exclusive Licensing Rights to BERLIN-CHEMIE for ONICIT®/ALOXI® and AKYNZEO® in Russia and CIS region
1/27/2020
Read more
MENARINI: Elcin Barker Ergun appointed as Group CEO
9/12/2019
Read more
Helsinn Group grants exclusive licensing rights to MENARINI for Pracinostat
12/21/2018
Read more
Art in a click: MENARINI launches “Pills of Art”
10/25/2018
Read more
1
2
3
4
LAST NEWS
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in
1/30/2023
Read more
Ibuprofen suspension – exemption to safeguard supply of the population
1/2/2023
Read more
Berlin becomes a transfer region for green chemistry
10/6/2022
Read more
BERLIN-CHEMIE celebrates 30 years of affiliation to the MENARINI Group
9/6/2022
Read more
News archive
Archive
Expand/Collapse
2023
(2)
2023, January
(2)
Expand/Collapse
2022
(5)
2022, October
(1)
2022, September
(1)
2022, July
(1)
2022, May
(2)
Expand/Collapse
2021
(3)
2021, November
(1)
2021, October
(1)
2021, April
(1)
Expand/Collapse
2020
(7)
2020, November
(1)
2020, October
(1)
2020, July
(1)
2020, June
(2)
2020, May
(1)
2020, January
(1)
Expand/Collapse
2019
(1)
2019, September
(1)
Expand/Collapse
2018
(5)
2018, December
(1)
2018, October
(1)
2018, September
(1)
2018, March
(2)
Expand/Collapse
2017
(4)
2017, June
(1)
2017, March
(2)
2017, January
(1)
Expand/Collapse
2016
(6)
2016, December
(2)
2016, November
(1)
2016, October
(1)
2016, May
(1)
2016, March
(1)
Responsibility >>
BERLIN-CHEMIE
International >>
SCROLL TO TOP